Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Teladoc delivered a mixed result and managed to surpass Wall Street expectations on the revenue front but its losses were more than market expectations.</li><li>The management continues its efforts towards creating solutions that change how customers engage with the healthcare system.</li><li>This growth builds on the company’s current relationship in chronic care and will give plan members access to a wide range of integrated primary and chronic care options.</li></ul>

Teladoc delivered a mixed result and managed to surpass Wall Street expectations on the revenue front but its losses were more than market expectations.The management continues its efforts towards creating solutions that change how customers engage with the healthcare system.This growth builds on the company’s current relationship in chronic care and will give plan members access to a wide range of integrated primary and chronic care options.

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>
<a href="https://www.smartkarma.com/entities/teladoc-health-inc" target="_blank" data-smartkarma-citation="entities:14233:1" rel="noopener">Teladoc Health, Inc. (TDOC US)</a> reported mixed Q2 results, with revenue and adjusted EBITDA coming in above the midpoint of guidance range. However, EPS came significantly below consensus and guidance.</li>
<li>Teladoc has already took $9.8 billion hit from impairment charge in H1 2022. Moreover, the company now expects results to be toward the lower end of already reduced guidance range.</li>
<li>Since publishing Q1 results in April, the stock plummeted 23% in three months. From its peak in February 2021, the stock is now down 85%. No immediate recovery is expected.  </li>
</ul>



Teladoc Health, Inc. (TDOC US) reported mixed Q2 results, with revenue and adjusted EBITDA coming in above the midpoint of guidance range. However, EPS came significantly below consensus and guidance.
Teladoc has already took $9.8 billion hit from impairment charge in H1 2022. Moreover, the company now expects results to be toward the lower end of already reduced guidance range.
Since publishing Q1 results in April, the stock plummeted 23% in three months. From its peak in February 2021, the stock is now down 85%. No immediate recovery is expected.  


Teladoc Health Inc (TDOC US): Q2 Revenue Beat Expectations; Here Is Why the Stock Toppled

SPAC Deep Dive, subSPAC

subSPAC

SPAC Deep Dive

Each week we’ll identify and break down for you SPACs that are capturing market share and making an impact.

<ul><li>Fledgling Digital Therapy Company Talkspace has seen its shares collapse amidst a string of unfavourable events, including fading pandemic tailwinds, management changes and mounting losses.</li><li>With the company's valuation declining over 82% since the SPAC merger closing nearly a year ago, Talkspace has emerged as a lucrative acquisition target for larger cash-rich companies to consolidate their business.</li><li>Since the acquisition rumours of Talkspace hit Wall Street last month, shares of the company have surged over 60%.</li></ul>

Fledgling Digital Therapy Company Talkspace has seen its shares collapse amidst a string of unfavourable events, including fading pandemic tailwinds, management changes and mounting losses.With the company's valuation declining over 82% since the SPAC merger closing nearly a year ago, Talkspace has emerged as a lucrative acquisition target for larger cash-rich companies to consolidate their business.Since the acquisition rumours of Talkspace hit Wall Street last month, shares of the company have surged over 60%.

Is Talkspace a Compelling Acquisition Target?

Equity Capital Markets

Teladoc Health, Inc. / Equity Capital Markets

<ul><li>Teladoc had a decent quarter with total revenue increasing by 25% year over year to $565 million.</li><li>The company ended the quarter with 54.3 million paid members in the United States, up 680,000 from the previous quarter.</li><li>The management anticipates revenue of $2.4 billion to $2.5 billion for 2022, representing an increase of 18% to 23% over the previous year with total paid membership in the United States to reach 54 million to 56 million members, representing a year-over-year increase of 1% to 5%.</li></ul>

Teladoc had a decent quarter with total revenue increasing by 25% year over year to $565 million.The company ended the quarter with 54.3 million paid members in the United States, up 680,000 from the previous quarter.The management anticipates revenue of $2.4 billion to $2.5 billion for 2022, representing an increase of 18% to 23% over the previous year with total paid membership in the United States to reach 54 million to 56 million members, representing a year-over-year increase of 1% to 5%.

Teladoc Inc.: What Is The Way Ahead For This Telehealth Pioneer? Check Out The Key Drivers

<ul>
<li>
<a href="https://www.smartkarma.com/entities/teladoc-health-inc" target="_blank" data-smartkarma-citation="entities:14233:1" rel="noopener">Teladoc Health, Inc. (TDOC US)</a> reported Q1 results, in-line with its prior guidance. However, 2022 guidance cut has played the spoilsport.</li>
<li>Teladoc shares plummeted more than 40% in 2022 to trade near 52-week low. With the near-term noises persist, shares will need time to recover.</li>
<li>With the current market dynamics in certain areas of operation not in favor of Teladoc, recent downfall in shares does not represent an attractive buying opportunity.</li>
</ul>



Teladoc Health, Inc. (TDOC US) reported Q1 results, in-line with its prior guidance. However, 2022 guidance cut has played the spoilsport.
Teladoc shares plummeted more than 40% in 2022 to trade near 52-week low. With the near-term noises persist, shares will need time to recover.
With the current market dynamics in certain areas of operation not in favor of Teladoc, recent downfall in shares does not represent an attractive buying opportunity.


Teladoc Health Inc (TDOC US): 1Q22 Results Review- Revenue Missed, 2022 Guidance Reduced

United States

Teladoc Health, Inc. provides healthcare services. The Company diagnoses, recommends treatment, and prescribes medication for routine medical issues through phone and video consultations. Teladoc operates in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Teladoc Health, Inc. (TDOC US)

Teladoc Inc: Major Drivers

Teladoc delivered a mixed result and managed to surpass Wall Street expectations on the revenue front but its losses were more than market...

Baptista Research